AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MDWD

Fox David Morton purchased $50K of MDWD

Fox David Morton purchased 3,537 shares of MediWound Ltd. (MDWD) at an average of $14.11 ($14.00–$14.23) across 3 trades on 2026-06-01.

Original reporting
SEC EDGAR · Fox David Morton
Published Jun 2, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDWD
Bullish
medium confidence
Mentioned
$MDWD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDWDBullishLow
01

Why it matters

The filing provides fresh, primary‑source information about insider activity, but the transaction size is modest.

02

Market read

Small insider purchase; limited immediate trading impact.

03

What to watch

Potential upcoming clinical data or financing needs could be the real driver behind the insider's confidence.

Relevance 4/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses a director's recent open‑market purchase of MDWD shares.

Company-level read

Ticker impact

$MDWDBullishMedium confidence
Context

Director Fox David Morton purchased 3,537 MDWD shares (~$50K) via open-market trades on 2026-06-01.

Expected impact

modest upward pressure as market prices in the insider purchase

Evidence & confidence

The purchase is small relative to market cap, but director-level buying is viewed positively by traders.

Market effects

Sector

Limited impact on the biotech sector; insider activity is routine.

Regional

No significant regional effect; transaction confined to US market.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The purchase is too small to affect price; market may ignore it.

Key entities

  • company
    MediWound Ltd.

    Biotech company listed on Nasdaq under ticker MDWD.

  • person
    Fox David Morton

    Director of MediWound Ltd. who executed the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDWD insider trading history →

Related articles

$MDWDMed

A sale of 1.2 million MediWound shares is expected to close around Nov. 5.

MediWound (MDWD) announced a share sale of 1.2 million ordinary shares, with H.C. Wainwright & Co. as underwriter. The deal is expected to close around Nov. 5, 2026, with gross proceeds estimated at approximately $30 million, assuming no exercise of the underwriter’s option. The company plans to use the net proceeds for working capital and general corporate purposes.

stocktitan.net
$MDWDHighAI 8/10

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)

MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.

investegate.co.uk
$MDWDMed

MediWound Ltd. (MDWD): Financial results for Q2 2026

MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it

SEC EDGAR 6-K